White Paper

2 Essential Approaches You Should be Using Now for Minimal Residual Disease Detection in Oncology

Minimal Residual Disease Detection: Key Considerations for Clinical Development in Oncology

As one of the most reliable predictors of treatment outcomes for multiple forms of cancer, Measurement of Residual Disease (MRD) testing presents many new opportunities for improvement in clinical trials.

In this complimentary white paper, discover best practices revealed by our top oncology experts in MRD testing that you should be using now in your drug development program. Our experts will also discuss the advantages and disadvantages of two leading approaches in MRD testing – Genomics and Flow Cytometry – and how to choose the most optimal one for your particular study.

Contact us today to discover how we can use our deep scientific expertise and global laboratory footprint to improve patient care in your MRD testing programs.


More Resources

How Immune Repertoire Sequencing Advances Immuno-oncology Biomarker Development Programs
Learn 3 Ways Anatomic Pathology Drives Advancements in Immuno-Oncology
Fighting Cancer: How Biomarker Testing and 3 Key Research Tools Shape Immunotherapy Drug Development
View All